Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS
Modern Rheumatology · 05.03.2026 · 36 (2) · 261-271
DOI: 10.1093/mr/roaf090 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, online erschienen am 10.10.2025. Verfasst von Satoshi Omura und 36 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Rituximab, Cyclophosphamide, Granulomatosis with Polyangiitis, Microscopic Polyangiitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI.
Abstract (Originalsprache)
Objectives
To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).
Methods
This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017–23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression.
Results
Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61–0.85), and for the composite outcome was 0.57 (95% CI: 0.33–0.97), and for serious infection was 1.03 (95% CI: 0.47–2.25). Results were robust in sensitivity analyses.
Conclusions
RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
- Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
- Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
- Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
ORCID-Profile: Satoshi Omura, Yutaka Kawahito
Förderung
- Japan Society for the Promotion of Science KAKENHI
Zitieren
APA
Omura, S., Kida, T., Kitai, J., Yanagida, T., Nakagomi, D., Abe, Y., Wada, M., Takizawa, N., Nomura, A., Kukida, Y., Kondo, N., Takagi, H., Endo, K., Hirata, S., Azuma, N., Takeuchi, T., Fukui, S., Kamada, K., Yanai, R., …, & Kawahito, Y. (2026). Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS. Modern Rheumatology, 36(2), 261-271. https://doi.org/10.1093/mr/roaf090
Vancouver
Omura S, Kida T, Kitai J, Yanagida T, Nakagomi D, Abe Y, et al. Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS. Modern Rheumatology. 2026;36(2):261-271. doi:10.1093/mr/roaf090
BibTeX
@article{Omura2026,
author = {Omura, Satoshi and Kida, Takashi and Kitai, Junya and Yanagida, Takuya and Nakagomi, Daiki and Abe, Yoshiyuki and Wada, Makoto and Takizawa, Naoho and Nomura, Atsushi and Kukida, Yuji and Kondo, Naoya and Takagi, Hirosuke and Endo, Koji and Hirata, Shintaro and Azuma, Naoto and Takeuchi, Tohru and Fukui, Shoichi and Kamada, Kazuro and Yanai, Ryo and Matsuo, Yusuke and Shimojima, Yasuhiro and Nishioka, Ryo and Okazaki, Ryota and Takata, Tomoaki and Moriyama, Mayuko and Takatani, Ayuko and Miyawaki, Yoshia and Shirai, Tsuyoshi and Dobashi, Hiroaki and Ito, Takafumi and Matsumoto, Isao and Takada, Toshihiko and Ito-Ihara, Toshiko and Yajima, Nobuyuki and Kawaguchi, Takashi and Seno, Takahiro and Kawahito, Yutaka},
title = {Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS},
journal = {Modern Rheumatology},
year = {2026},
volume = {36},
number = {2},
pages = {261--271},
doi = {10.1093/mr/roaf090}
}
EUVIMED